GMP 1 M Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The synergistic action of these two agents helps achieve better glycemic control than monotherapy, making GMP 1 M Tablet PR suitable for patients inadequately controlled on diet and exercise alone or those requiring combination therapy. This formulation is typically prescribed as part of a comprehensive diabetes management plan including diet modification and regular physical activity. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose levels and renal function is recommended. GMP 1 M Tablet PR should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks associated with antidiabetic therapy.